ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1952

Interest in Clinical Trial Participation Among People with Lupus: Results from the Research Accelerated by You (RAY) Registry
Abstract Number: 1347

Interest of DAS28-γGT in Assessing Cardiovascular Risk Activity in Rheumatoid Arthritis in Routine Practice
Abstract Number: 2288

Interferon Gamma Signaling Is Associated with Development of Extraglandular Manifestations in Sjögren’s Disease
Abstract Number: 0815

Interferon-stimulated Gene Expression in Non-lesional Skin Is Similarly Elevated in Incomplete SLE and SLE
Abstract Number: 0666

Interferon-stimulated Genes on Peripheral CD8+ T Cells of SLE Patients Were the Keys for Early Response to BAFF/APRIL-targeted Therapy
Abstract Number: 0901

Intergenic Alu Elements Are Uniquely Expressed in Dermatomyositis and Correlate with Interferon Stimulated Genes
Abstract Number: 0308

Interstitial Lung Disease as the First Clinical Manifestation of Connective Tissue Diseases
Abstract Number: 1608

Interstitial Lung Disease in ANCA-associated Vasculitis: A Retrospective Study of Clinical Characteristics, Radiographic Features, and Outcomes
Abstract Number: 2463

Interstitial Lung Disease in Very Early Systemic Sclerosis – a Clinical and Radiological Characterization
Abstract Number: 1186

Intra-articular Corticosteroid Injections for Knee Osteoarthritis: Does the Dose Matter?
Abstract Number: 2271

Intra-Articular Injection of Human Bone Marrow-Derived Mesenchymal Stem Cells in Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Trial
Abstract Number: 0281

Intra-articular Treatment Combining Sustained Release Colchicine Encapsulated in Microspheres, and Ropivacaine, Is Effective in Inflammatory Arthritis in Rats
Abstract Number: 0121

Intra-renal Involvement in Primary Antiphospholipid Antibodies Syndrome: Data from Two Italian Centers
Abstract Number: 1626

Intracranial Giant Cell Arteritis: A Comprehensive Systematic Review
Abstract Number: 1804

Investigating Adaptive Immune Receptor Repertoires by Deep Immune Cell Phenotyping in Preclinical Autoimmunity Development

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].